The Life Sciences team advised Disc Medicine in its $50 million Series A financing and exclusive license agreement with AbbVie for the worldwide rights to a series of hemojuvelin antagonist monoclonal antibodies.
Disc Medicine is a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases. The company's novel approach focuses on targeting hepcidin, a key regulator of iron metabolism, as a treatment for inherited and acquired anemias. AbbVie is a global biopharmaceutical company.
The Series A financing was led by life sciences investor Novo Holdings A/S along with Access Biotechnology, the life sciences investing arm of Access Industries, and founding investor Atlas Venture. Atlas, a leading biotech venture capital firm, seeded the company in 2017.